American Century Companies Inc. lessened its stake in ABIOMED, Inc. (NASDAQ:ABMD) by 18.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 329,209 shares of the medical equipment provider’s stock after selling 72,514 shares during the period. American Century Companies Inc. owned about 0.73% of ABIOMED worth $148,062,000 at the end of the most recent quarter.
A number of other institutional investors also recently added to or reduced their stakes in ABMD. MERIAN GLOBAL INVESTORS UK Ltd boosted its position in ABIOMED by 1,030.0% in the 3rd quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 638,856 shares of the medical equipment provider’s stock worth $287,325,000 after purchasing an additional 582,318 shares in the last quarter. Renaissance Technologies LLC boosted its position in ABIOMED by 35.0% in the 2nd quarter. Renaissance Technologies LLC now owns 1,551,423 shares of the medical equipment provider’s stock worth $634,610,000 after purchasing an additional 401,800 shares in the last quarter. FMR LLC boosted its position in ABIOMED by 34.2% in the 2nd quarter. FMR LLC now owns 691,818 shares of the medical equipment provider’s stock worth $282,988,000 after purchasing an additional 176,394 shares in the last quarter. Carillon Tower Advisers Inc. boosted its position in ABIOMED by 77.0% in the 2nd quarter. Carillon Tower Advisers Inc. now owns 400,348 shares of the medical equipment provider’s stock worth $163,762,000 after purchasing an additional 174,198 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. purchased a new stake in ABIOMED in the 2nd quarter worth approximately $58,965,000. Institutional investors and hedge funds own 87.14% of the company’s stock.
In related news, VP Michael G. Howley sold 10,000 shares of the stock in a transaction on Tuesday, September 25th. The stock was sold at an average price of $432.50, for a total value of $4,325,000.00. Following the completion of the transaction, the vice president now directly owns 48,954 shares of the company’s stock, valued at approximately $21,172,605. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Andrew J. Greenfield sold 4,440 shares of the stock in a transaction on Wednesday, August 29th. The shares were sold at an average price of $395.00, for a total value of $1,753,800.00. The disclosure for this sale can be found here. Corporate insiders own 3.50% of the company’s stock.
Shares of ABMD stock opened at $405.17 on Friday. The company has a market cap of $17.50 billion, a PE ratio of 165.38, a price-to-earnings-growth ratio of 3.18 and a beta of 0.35. ABIOMED, Inc. has a 1-year low of $186.72 and a 1-year high of $459.75.
ABIOMED (NASDAQ:ABMD) last announced its earnings results on Thursday, November 1st. The medical equipment provider reported $1.09 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.36. The business had revenue of $181.78 million during the quarter, compared to the consensus estimate of $175.41 million. ABIOMED had a return on equity of 20.09% and a net margin of 27.60%. The business’s quarterly revenue was up 36.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.54 EPS. Research analysts anticipate that ABIOMED, Inc. will post 3.57 earnings per share for the current year.
ABMD has been the topic of several recent research reports. Morgan Stanley upgraded ABIOMED from an “equal” rating to a “weight” rating and upped their price objective for the stock from $396.00 to $496.00 in a research report on Wednesday. Zacks Investment Research lowered ABIOMED from a “buy” rating to a “hold” rating in a research report on Tuesday, July 31st. BidaskClub upgraded ABIOMED from a “hold” rating to a “buy” rating in a research report on Wednesday, September 5th. BTIG Research raised ABIOMED from a “neutral” rating to a “buy” rating and set a $450.00 target price for the company in a research note on Friday, November 2nd. Finally, ValuEngine downgraded ABIOMED from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 18th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $402.78.
COPYRIGHT VIOLATION WARNING: “American Century Companies Inc. Sells 72,514 Shares of ABIOMED, Inc. (ABMD)” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2018/11/10/american-century-companies-inc-sells-72514-shares-of-abiomed-inc-abmd.html.
ABIOMED Company Profile
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.
See Also: Fundamental Analysis
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.